D N (Israel) Probability of Target Price Finishing Over Current Price

    DNA -- Israel Stock  

    ILS 25.40  0.80  3.05%

    D N probability of target price tool provides mechanism to make assumptions about upside and downside potential of D N A Biomedical Solutions Ltd performance during a given time horizon utilizing its historical volatility. Please specify D N time horizon, a valid symbol (red box) and a target price (blue box) you would like D N odds to be computed. Additionally see Investing Opportunities.
    Horizon     30 Days    Login   to change
    Symbol:
    Refresh Odds

    D N Target Price Odds to finish over

    Current PriceHorizonTarget PriceOdds to move above current price in 30 days
     25.40 30 days 25.40  ABOUT 37.99%
    Based on normal probability distribution, the odds of D N to move above current price in 30 days from now is about 37.99% (This D N A Biomedical Solutions Ltd probability density function shows the probability of D N Stock to fall within a particular range of prices over 30 days) .
    Assuming 30 trading days horizon, D N has beta of 0.0856 suggesting as returns on market go up, D N average returns are expected to increase less than the benchmark. However during bear market, the loss on holding D N A Biomedical Solutions Ltd will be expected to be much smaller as well. Additionally D N A Biomedical Solutions Ltd has an alpha of 0.1865 implying that it can potentially generate 0.1865% excess return over DOW after adjusting for the inherited market risk (beta).
     D N Price Density 
          Price 
    α
    Alpha over DOW
    =0.19
    β
    Beta against DOW=0.09
    σ
    Overall volatility
    =6.55
    Ir
    Information ratio =0.09

    D N Alerts

    D N Alerts and Suggestions

    D N A is not yet fully synchronised with the market data
    D N A has high likelihood to experience some financial distress in the next 2 years
    The company has accumulated 0 in total debt. D N A Biomedical Solutions Ltd has Current Ratio of 0.18 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
    This company reported revenue of . Net Loss for the year was (55.48M).
    DNA BIOMED SOLUT has accumulated about 1.52M in cash with (1.91M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
    Additionally see Investing Opportunities. Please also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.
    Search macroaxis.com